Cargando…
Subgroup identification for treatment selection in biomarker adaptive design
BACKGROUND: Advances in molecular technology have shifted new drug development toward targeted therapy for treatments expected to benefit subpopulations of patients. Adaptive signature design (ASD) has been proposed to identify the most suitable target patient subgroup to enhance efficacy of treatme...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673750/ https://www.ncbi.nlm.nih.gov/pubmed/26646831 http://dx.doi.org/10.1186/s12874-015-0098-7 |
_version_ | 1782404800186417152 |
---|---|
author | Lu, Tzu-Pin Chen, James J. |
author_facet | Lu, Tzu-Pin Chen, James J. |
author_sort | Lu, Tzu-Pin |
collection | PubMed |
description | BACKGROUND: Advances in molecular technology have shifted new drug development toward targeted therapy for treatments expected to benefit subpopulations of patients. Adaptive signature design (ASD) has been proposed to identify the most suitable target patient subgroup to enhance efficacy of treatment effect. There are two essential aspects in the development of biomarker adaptive designs: 1) an accurate classifier to identify the most appropriate treatment for patients, and 2) statistical tests to detect treatment effect in the relevant population and subpopulations. We propose utilization of classification methods to identity patient subgroups and present a statistical testing strategy to detect treatment effects. METHODS: The diagonal linear discriminant analysis (DLDA) is used to identify targeted and non-targeted subgroups. For binary endpoints, DLDA is directly applied to classify patient into two subgroups; for continuous endpoints, a two-step procedure involving model fitting and determination of a cutoff-point is used for subgroup classification. The proposed strategy includes tests for treatment effect in all patients and in a marker-positive subgroup, with a possible follow-up estimation of treatment effect in the marker-negative subgroup. The proposed method is compared to the ASD classification method using simulated datasets and two publically available cancer datasets. RESULTS: The DLDA-based classifier performs well in terms of sensitivity, specificity, positive and negative predictive values, and accuracy in the simulation data and the two cancer datasets, with superior accuracy compared to the ASD method. The subgroup testing strategy is shown to be useful in detecting treatment effect in terms of power and control of study-wise error. CONCLUSION: Accuracy of a classifier is essential for adaptive designs. A poor classifier not only assigns patients to inappropriate treatments, but also reduces the power of the test, resulting in incorrect conclusions. The proposed procedure provides an effective approach for subgroup identification and subgroup analysis. |
format | Online Article Text |
id | pubmed-4673750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46737502015-12-10 Subgroup identification for treatment selection in biomarker adaptive design Lu, Tzu-Pin Chen, James J. BMC Med Res Methodol Research Article BACKGROUND: Advances in molecular technology have shifted new drug development toward targeted therapy for treatments expected to benefit subpopulations of patients. Adaptive signature design (ASD) has been proposed to identify the most suitable target patient subgroup to enhance efficacy of treatment effect. There are two essential aspects in the development of biomarker adaptive designs: 1) an accurate classifier to identify the most appropriate treatment for patients, and 2) statistical tests to detect treatment effect in the relevant population and subpopulations. We propose utilization of classification methods to identity patient subgroups and present a statistical testing strategy to detect treatment effects. METHODS: The diagonal linear discriminant analysis (DLDA) is used to identify targeted and non-targeted subgroups. For binary endpoints, DLDA is directly applied to classify patient into two subgroups; for continuous endpoints, a two-step procedure involving model fitting and determination of a cutoff-point is used for subgroup classification. The proposed strategy includes tests for treatment effect in all patients and in a marker-positive subgroup, with a possible follow-up estimation of treatment effect in the marker-negative subgroup. The proposed method is compared to the ASD classification method using simulated datasets and two publically available cancer datasets. RESULTS: The DLDA-based classifier performs well in terms of sensitivity, specificity, positive and negative predictive values, and accuracy in the simulation data and the two cancer datasets, with superior accuracy compared to the ASD method. The subgroup testing strategy is shown to be useful in detecting treatment effect in terms of power and control of study-wise error. CONCLUSION: Accuracy of a classifier is essential for adaptive designs. A poor classifier not only assigns patients to inappropriate treatments, but also reduces the power of the test, resulting in incorrect conclusions. The proposed procedure provides an effective approach for subgroup identification and subgroup analysis. BioMed Central 2015-12-09 /pmc/articles/PMC4673750/ /pubmed/26646831 http://dx.doi.org/10.1186/s12874-015-0098-7 Text en © Lu and Chen. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Lu, Tzu-Pin Chen, James J. Subgroup identification for treatment selection in biomarker adaptive design |
title | Subgroup identification for treatment selection in biomarker adaptive design |
title_full | Subgroup identification for treatment selection in biomarker adaptive design |
title_fullStr | Subgroup identification for treatment selection in biomarker adaptive design |
title_full_unstemmed | Subgroup identification for treatment selection in biomarker adaptive design |
title_short | Subgroup identification for treatment selection in biomarker adaptive design |
title_sort | subgroup identification for treatment selection in biomarker adaptive design |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673750/ https://www.ncbi.nlm.nih.gov/pubmed/26646831 http://dx.doi.org/10.1186/s12874-015-0098-7 |
work_keys_str_mv | AT lutzupin subgroupidentificationfortreatmentselectioninbiomarkeradaptivedesign AT chenjamesj subgroupidentificationfortreatmentselectioninbiomarkeradaptivedesign |